Milatuzumab

Milatuzumab

Monoclonal antibody
Type	Whole antibody
Source	Humanized (from mouse)
Target	CD74
Clinical data
ATC code	none
Identifiers
CAS Number	899796-83-9 N
ChemSpider	none
UNII	2OP4E0GC6V
KEGG	D08944 Y
Chemical and physical data
Formula	C6518H10066N1758O2020S40
Molar mass	146658.91 g·mol−1
NY (what is this?)  (verify)

Milatuzumab (or hLL1) is an anti-CD74^[1] humanized monoclonal antibody for the treatment of multiple myeloma non-Hodgkin's lymphoma and chronic lymphocytic leukemia.^[2][3]

The drug is the first anti-CD74 antibody that has entered into human testing and is currently being studied for the treatment of multiple myeloma. Milatuzumab has received orphan drug designation from the Food and Drug Administration in the United States for the treatment of multiple myeloma and chronic lymphocytic leukemia.

Milatuzumab was developed by Immunomedics, Inc, (Morris Plains NJ USA).

This article appears to contradict the article CD74. Please discuss at the talk page and do not remove this message until the contradictions are resolved. (November 2015)

This section needs additional citations for verification. Please help improve this article by adding citations to reliable sources in this section. Unsourced material may be challenged and removed. (November 2015) (Learn how and when to remove this message)

CD74 is present on a variety of hematological tumors and even on some solid cancers. It is present in limited amounts in normal tissues but widely found in leukemias, lymphomas and the vast majority of multiple myeloma cases.^{[citation needed]} CD74 is involved in a cell-to-cell communication pathway that is critical for survival.^{[citation needed]} When CD74 is blocked by milatuzumab, it can lead to cell death.

CD74 is an attractive target for a drug conjugate because of its rapid internalizing property.^{[citation needed]}

In preclinical studies with human lymphomas and myelomas, both naked Milatuzumab and the Milatuzumab conjugated with doxorubicin,^[4] an antibody-drug conjugate or ADC, have demonstrated anti-lymphoma activity in-vivo.

hLL1-Dox

Milatuzumab has been linked to doxorubicin to form an antibody-drug conjugate or ADC (known as hLL1-Dox or IMMU-110) for treatment of relapsed multiple myeloma. A Phase I/II clinical trial to evaluate this milatuzumab-doxorubicin conjugate began in 2010,^[5][6] but was terminated in 2021 due to lack of efficacy.^[7]